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OBJECTIVES We sought to examine whether estradiol (E2) supplementation suppresses anginal attacks in
women with variant angina.
BACKGROUND Estrogen is known to improve endothelial function. Coronary spasm plays an important role
in the pathogenesis of not only variant angina but also ischemic heart disease in general, and
endothelial dysfunction seems to be involved in the pathogenesis of coronary spasm.
METHODS Fifteen postmenopausal women with variant angina (mean age 54.2 years) were given a
hyperventilation (HV) test, a provocation test for coronary spasm, in the early morning of day
1 (baseline), day 3 (after 2-day transdermal E2 supplementation, 4 mg) and day 5 (after 2-day
placebo administration). We measured the flow-mediated (endothelium-dependent) dilation
(FMD) of the brachial artery with the ultrasound technique before each HV test.
RESULTS The anginal attacks with ST segment elevation were induced by HV in all patients on days
1 and 5. However, no attacks were induced on day 3. Supplementation with E2 augmented
FMD (3.5 6 0.6*, 8.9 6 0.7 and 4.0 6 0.5* on days 1, 3 and 5, respectively; *p , 0.01 vs.
day 3). The serum E2 levels on days 1, 3 and 5 were 22.7 6 2.8*, 96.2 6 9.2 and 30.7 6 7.1*
pg/ml, respectively (*p , 0.01 vs. day 3).
CONCLUSIONS The present results demonstrated for the first time, to our knowledge, that E2 supplemen-
tation suppresses the HV-induced attacks in women with variant angina, in part because of
the improvement of endothelial function. (J Am Coll Cardiol 2001;37:735–40) © 2001 by
the American College of Cardiology
Coronary spasm plays an important role in the pathogenesis
of not only variant angina but also ischemic heart disease in
general (1). The incidence of ischemic heart disease is
relatively uncommon in premenopausal women, but shows a
sharp rise after natural or surgical menopause (2). The
decline of endogenous ovarian hormones is commonly
assumed to be a major component of this phenomenon
(2–4).
Estrogen improves lipid profiles (3,4), stimulates
endothelium-derived nitric oxide (NO) and prostacyclin
production/release, scavenges superoxide and decreases
endothelin-1 activity (5). These effects serve to slow the
development and to limit the adverse effects of atheroscle-
rosis, in part by amelioration of vascular endothelial dys-
function (6). As endothelial dysfunction is reported to be
one of the reasons for coronary spasm (7–9), estrogen may
further be effective for suppression of coronary spasm itself.
The hyperventilation (HV) test was previously reported to
be an effective noninvasive provocation test for coronary
spasm in patients with variant angina (7,10). The present
study was designed to examine whether estrogen replace-
ment suppresses the HV-induced attacks in women with
variant angina.
METHODS
Study patients. In the present study, variant angina was
defined as recurrent attacks of chest oppression occurring
spontaneously at rest, with ST segment elevation on the
electrocardiogram (ECG), rapidly relieved by nitroglycerin.
Fifteen postmenopausal women (mean age 54.2 years old)
admitted to our institution from April 1997 to April 2000
met these criteria and were enrolled in the study. All of
them had proven coronary spasm by chest oppression and
ST segment elevation after intracoronary injection of ace-
tylcholine (ACh) (11,12). No patient showed fixed coronary
stenosis after administration of nitroglycerin, as assessed by
cardiac catheterization. No patient had diabetes, a history of
myocardial infarction or evidence of impaired left ventricu-
lar function at rest, as assessed by echocardiography and
cardiac catheterization.
All antianginal drugs, except sublingual nitroglycerin,
were stopped at least seven days before the study. The
clinical details of the patients were kept unknown to all
investigators participating in data collection and analysis.
All patients gave written, informed consent, and the study
was conducted in accordance with the guidelines approved
by the Ethics Committee at our institution.
Coronary angiography. Before study entry, coronary an-
giography was performed in all patients by using the
Judkin’s technique. Coronary spasm was provoked by intra-
coronary injection of ACh into the right and left coronary
arteries separately, as described in our previous reports
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(11,12). The appearance of total or subtotal occlusion of a
major coronary artery associated with ST segment deviation
on the ECG was considered to be a manifestation of
coronary spasm (11,12). After intracoronary injection of
nitroglycerin, the coronary angiograms were filmed in mul-
tiple projections. The stenotic lesion was quantitatively
analyzed using Cardio 500 (Kontron Instruments, Eching,
Germany) (8,9). Significant coronary stenosis was defined as
.50% lumen diameter narrowing.
Study protocol. All patients were treated with an estradiol-
17-beta (E2) patch (Estraderm TTS, Novartis, Basal, Swit-
zerland; 4 mg) for two days and a placebo patch correspond-
ing to E2 for another two days. Because anginal attacks are
most easily induced in the early morning (7,10), the HV
test, a provocation test for coronary spasm, was performed at
7:00 AM during the fasting state on day 1 (baseline), day 3
(after E2 supplementation) and day 5 (after placebo admin-
istration). The study protocol is shown in Figure 1A.
On each study day, the patients underwent the following
procedures. They were asked to hyperventilate vigorously
for 6 min (10). Three ECG leads (V3,V5 and aVF) were
continuously monitored on an oscilloscope (Case IV, Mar-
quette, Milwaukee) from 20 min before to 15 min after HV.
Twelve-lead ECGs were recorded every minute during and
up to 10 min after HV. Blood pressure was measured with
a cuff sphygmomanometer at appropriate intervals. If chest
pain or ischemic ST segment changes on the ECG appeared
during HV, the test was terminated immediately. The
change on the ECG was defined as positive with ST
segment elevation .0.1 mV, as compared with the baseline
level, at 80 ms after the onset of the J point. The HV test
was considered positive if ischemic ST segment changes
were induced by HV.
Vascular studies. Endothelial function was evaluated by
flow-mediated (endothelium-dependent) dilation (FMD)
of the brachial artery, as measured with the ultrasound
technique. The measurement was performed before every
HV test, as shown in Figure 1, A and B. The validity of this
method has been demonstrated in our previous studies and
by others (13–18). In brief, the diameter of the brachial
artery was measured from B-mode ultrasound images using
a 7.5-MHz linear array transducer (SSH-160A, Toshiba,
Tokyo, Japan), and flow velocity was measured using a
pulsed Doppler signal. The brachial artery images were
obtained in the antecubital fossa in a longitudinal fashion.
This location on the brachium was marked, and all subse-
quent images were obtained at the same location. Depth and
gain settings were optimized at the beginning of the
measurement and were kept constant throughout the re-
cording period. The optimal location of the transducer and
the machine settings were recorded for each subject to
ensure that the vascular reactivity measurements were per-
formed under the same conditions at each study.
Each subject lay quietly for 10 min before the first scan.
After baseline measurements of the diameter of and flow
velocity in the brachial artery, a blood pressure cuff placed
around the forearm was inflated to 250 to 300 mm Hg and
was released after 5 min. Measurements of the arterial
diameter and flow velocity were continuously taken during
cuff inflation and after cuff deflation. After the HV test,
sublingual nitroglycerin (0.3 mg) was administrated to all
subjects, and 5 min later the nitroglycerin-induced dilation
was measured (Fig. 1B).
The ultrasound images were recorded on a super-VHS
video cassette recorder (BR-S601M, Victor, Tokyo, Japan),
and the arterial diameter was measured at a fixed distance
from an anatomic marker with ultrasonic calipers by two
independent observers who had no knowledge of which
treatment the patients had been receiving. The measure-
ments were taken from the anterior to the posterior interface
between the media and adventitia (“m” line) at end diastole,
incident with the R wave on a continuously recorded ECG
(13–19). The diameters at four cardiac cycles were analyzed
for each scan and were averaged. The peak diameter for
reactive hyperemia was measured for 45 to 90 s after cuff
deflation (13–17). Blood flow was calculated by multiplying
the velocity–time integral of the Doppler flow signal by
heart rate and the vessel cross-sectional area. Increase in
blood flow was calculated by dividing the maximal blood
flow within the first 15 s after cuff deflation by the blood
flow at baseline (13–17).
The interobserver and intraobserver variabilities for the
repeated measurements of the rest arterial diameter were
0.05 6 0.02 and 0.02 6 0.02 mm, respectively. In a
preliminary study, when these procedures were performed at
the same time on two separate days in 20 volunteers, the
average intrasubject test–retest difference for the measure-
ments of the arterial diameter during reactive hyperemia was
0.05 6 0.04 mm (13,15).
Blood sampling and assay. Blood samples for evaluation
of serum levels of E2 were obtained before each HV test and
Abbreviations and Acronyms
ACh 5 acetylcholine
ECG 5 electrocardiogram
E2 5 estradiol
FMD 5 flow-mediated (endothelium-dependent)
dilation
HV 5 hyperventilation
NO 5 nitric oxide
Figure 1. Schematic representation of the experimental protocol.
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were measured by a specific immunoradiometric assay (Di-
agnostic Products Corporation, Los Angeles, California)
(13,14). Arterial blood samples for pH and gas analysis were
obtained from the femoral artery before and at the end of
each HV test and were measured with an autoanalyzer
(ABL-2, Radiometer Medical, Copenhagen, Denmark).
Statistical analysis. The data were analyzed by analysis of
variance. When statistically significant effects were found,
the Newman-Keuls test was used to isolate the differences
between groups. Hemodynamic variables, arterial blood pH
and blood gases before and after HV were compared by
using the two-tailed paired t test. Statistical significance was
set at p , 0.05. All data are expressed as the mean value 6
SE.
RESULTS
Coronary angiography. Coronary angiography was per-
formed in all subjects. Intracoronary injection of ACh could
provoke coronary spasm with ST segment elevation and
chest symptoms in all subjects (Table 1). After intracoronary
injection of nitroglycerin, fixed coronary artery stenosis was
not documented in any subject.
Anginal attacks induced by HV. Most patients experi-
enced mild light-headedness and numbness of the hands
and feet, which began 2 to 3 min after the beginning and
continued to the end of the HV test. On day 1 (baseline),
anginal attacks occurred after HV in all patients. On day 3
(after E2 supplementation), no anginal attacks occurred
either during or after HV. On day 5 (after placebo admin-
istration), the anginal attacks occurred again after HV in all
patients. All 30 attacks recorded on days 1 and 5 were
associated with ST segment elevation. The attacks occurred
1 to 4 min after the end of HV and spontaneously
disappeared within a few minutes. Every patient had anginal
pain during the attack. A representative case (subject no. 1)
is shown in Figure 2.
Arterial blood pH and gases before and after HV. After
HV, arterial pH increased from 7.39 6 0.05 to 7.56 6 0.08
(p , 0.01) on day 1 (baseline), from 7.40 6 0.08 to 7.57 6
0.10 (p , 0.01) on day 3 (after E2 supplementation) and from
7.40 6 0.06 to 7.59 6 0.10 (p , 0.01) on day 5 (after placebo
administration). Arterial blood partial carbon dioxide pressure
decreased from 40 6 6 to 26 6 7 mm Hg (p , 0.01) on day
1, from 41 6 5 to 24 6 8 mm Hg (p , 0.01) on day 3 and
from 41 6 6 to 25 6 6 mm Hg (p , 0.01) on day 5. Arterial
blood oxygen partial pressure increased from 92 6 13 to 114 6
20 mm Hg (p , 0.01) on day 1, from 93 6 12 to 112 6
25 mm Hg (p , 0.01) on day 3 and from 92 6 14 to 115 6
21 mm Hg (p , 0.01) on day 5 after HV. There were no
significant differences in these variables among the three study
days either before or after HV (Table 2).
Effects of E2 on FMD. Supplementation with E2 did not
elicit any changes in heart rate, mean blood pressure, basal
arterial diameter, basal blood flow or percent increase in
blood flow during reactive hyperemia (Table 2). Significant
improvement was observed in FMD after E2 supplementa-
tion (3.5 6 0.6%*, 8.9 6 0.7% and 4.0 6 0.5%* on days 1,
3 and 5, respectively (*p , 0.01 vs. day 3). After placebo
administration, FMD declined to a level comparable to that
at baseline. The serum E2 levels increased after E2 supple-
mentation and decreased to the baseline levels after placebo
administration (22.7 6 2.8*, 96.2 6 9.2 and 30.7 6 7.1*
pg/ml on days 1, 3 and 5, respectively (*p , 0.01 vs. day 3).
There were no significant changes in the nitroglycerin-
induced vasodilation throughout the study (Table 2).
DISCUSSION
The present study clearly showed that E2 supplementation
completely suppresses the HV-induced attacks in post-
menopausal women with variant angina. On day 1 (base-
line) and day 5 (after placebo administration), the anginal
attacks were induced by HV in all patients. Nevertheless, no
Table 1. Clinical Characteristics of the Subjects
Subject
No.
Age
(yrs)
Smoking
Status
Total
Cholesterol
(mg/dl)
HDL
Cholesterol
(mg/dl)
LDL
Cholesterol
(mg/dl)
TG
(mg/dl) Spasm Artery
ST Segment Elevation Site
During Hyperventilation
Test (lead)
1 57 No 209 46 141 108 RCA II, III, aVF
2 51 Yes 214 40 158 79 LAD V1–5
3 56 No 176 60 95 106 LAD, LCx V1–4
4 59 Yes 217 56 131 151 RCA II, III, aVF
5 52 Yes 222 52 139 156 RCA II, III, aVF
6 49 Yes 193 47 121 125 LAD V2–6
7 45 Yes 146 50 75 105 LAD V2–6
8 56 Yes 237 83 122 160 LAD, RCA V2–6
9 55 Yes 201 52 122 136 RCA II, III, aVF
10 57 Yes 185 46 120 95 LAD V2–6
11 59 Yes 224 53 149 112 RCA II, III, aVF
12 51 Yes 221 44 152 126 RCA, LAD II, III, aVF
13 49 No 212 69 117 132 RCA, LAD, LCx II, III, aVF, V2–6
14 60 No 255 57 166 161 RCA II, III, aVF
15 58 Yes 232 54 149 146 RCA II, III, aVF
HDL 5 high density lipoprotein; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; LDL 5 low density lipoprotein; RCA 5 right coronary
artery; TG 5 triglycerides.
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attacks occurred on day 3 (after E2 supplementation),
although the degree of HV was comparable among the three
study days, as assessed by arterial blood pH and gases.
We previously reported that the HV-induced attacks in
patients with variant angina pectoris were due to coronary
spasm (7,10). In all patients enrolled in the present study,
Table 2. Hemodynamic Variables and Arterial Blood pH and Gases
Day 1 Day 3 Day 5
Before HV After HV Before HV After HV Before HV After HV
Heart rate (beats/min) 62.1 6 2.1 63.0 6 2.0 63.1 6 1.9 62.4 6 1.8 61.5 6 2.6 62.5 6 2.1
Mean BP (mm Hg) 105.2 6 2.9 104.9 6 3.0 106.9 6 3.1 105.9 6 3.5 106.1 6 2.8 105.4 6 3.2
Basal arterial diameter (mm) 3.31 6 0.12 — 3.25 6 0.22 — 3.32 6 0.26 —
Basal blood flow (ml/min) 278.3 6 31.2 — 275.8 6 29.6 — 278.6 6 29.6 —
Increase in flow during reactive
hyperemia (%)
256.3 6 36.3 — 261.2 6 35.2 — 261.8 6 34.5 —
Flow-mediated vasodilation (%) 3.5 6 0.6* — 8.9 6 0.7 — 4.0 6 0.5* —
Nitroglycerin-induced vasodilation (%) 19.8 6 2.1 — 20.4 6 1.5 — 19.8 6 2.5
Serum estradiol level (pg/ml) 22.7 6 2.8* — 96.2 6 9.2 — 30.7 6 7.1* —
pH 7.39 6 0.05 7.56 6 0.08 7.40 6 0.08 7.57 6 0.10 7.40 6 0.06 7.59 6 0.10
PCO2 (mm Hg) 40 6 6 26 6 7 41 6 5 24 6 8 41 6 6 25 6 6
PO2 (mm Hg) 92 6 13 114 6 20 93 6 12 112 6 25 92 6 14 115 6 21
*p , 0.01 vs. day 3. Data are presented as the mean value 6 SE.
BP 5 blood pressure; HV 5 hyperventilation test; PCO2 5 partial carbon dioxide pressure; PO2 5 partial oxygen pressure.
Figure 2. A representative case (case 1). At baseline (day 1), the hyperventilation (HV) test induced anginal attacks with ST segment elevation in leads II,
III and aVF and depression in leads I and aVL (A), but not after estradiol (E2) supplementation (day 3) (B). After placebo administration (day 5), the HV
test again induced anginal attacks with ST segment elevation in leads II, III and aVF and depression in leads I and aVL (C).
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the anginal attack was induced by intracoronary injection of
ACh, and coronary spasm was observed on the coronary
angiogram. Taken together, the present results suggest that
E2 supplementation suppressed the HV-induced attacks by
relieving coronary spasm.
Probable mechanism. Estrogen has been demonstrated to
increase NO synthase activity in the vascular endothelium
(5). In the present study, the magnitude of FMD of the
brachial artery during reactive hyperemia after transient
occlusion, which is mainly endothelium-derived NO depen-
dent (20), increased after E2 supplementation and decreased
to baseline levels after placebo administration. Nitroglycerin-
induced, endothelium-independent vasodilation remained un-
changed. That is to say, E2 supplementation improved the
endothelial function of the brachial artery. As estrogens have
been reported to improve endothelial function in humans, as
reported in our previous studies (13,14) and by others (5), the
present results are in agreement with the previous studies.
Endothelium-dependent vasodilation has been shown to
play a crucial role in the regulation of vascular tone
(6,21–24). We have previously reported that patients with
coronary spasm have a disturbance in endothelial function
of the coronary arteries, as well as a hypercontractile
response of vascular smooth muscle (7–9,25). The subjects
included in this study had a disturbance of endothelium-
regulated coronary artery vasomotor function, for all of
them showed coronary spasm with ACh, which causes
vasodilation when the endothelium is functioning normally
(21–23). We have provided evidence for endothelial dys-
function not only in the coronary arteries, but also in the
brachial arteries in the patients with coronary spasm (15).
Because there is a close linkage between endothelial func-
tion of the brachial artery and that of the coronary arteries
(15,18), this modulation of endothelium-dependent dilation
in the brachial artery observed in the present study most
likely takes place in the coronary arteries as well.
Administration of E2 is reported to modulate the coro-
nary artery responses induced by ACh in women with
coronary heart disease (26). Estrogen is also known to
directly relax vascular smooth muscle by antagonizing cal-
cium channels (27). Therefore, it can be presumed that
estrogen supplementation affects endothelial and smooth
muscle function and contributes to suppression of HV-
induced anginal attacks.
Reactive hyperemia after temporary interruption of the
blood flow may result from an interplay between physical
(myogenic) and local metabolic factors, including prosta-
glandins and adenosine (28,29). Increased wall shear stress
owing to an increase in blood flow results in the production
of endothelium-derived vasodilators, including NO (21,24).
We have demonstrated that after transient arterial occlu-
sion, NO plays a major role in the duration of hyperemia or
flow debt repayment, but not in peak reactive hyperemia
(30). In fact, local administration of the NO synthase
inhibitor NG-monomethyl-L-arginine did not affect the
peak increase in blood flow during reactive hyperemia in
human peripheral conduit arteries (20). This may explain
why the comparable increases were observed in peak blood
flow on days 1, 3 and 5, despite the differences in FMD.
Study limitations. In the present study, a double dose of
E2 (4 mg/day for 2 days) was administered to the patients
for a short period, instead of common hormone replacement
therapy. It was not confirmed that E2 improved coronary
endothelial function in the postmenopausal women with
variant angina. Further study is needed to examine whether
long-term supplementation of smaller dose of E2 is also
effective in suppressing the anginal attacks, and whether E2
improves coronary endothelial function in postmenopausal
women with variant angina.
Conclusions. The present study demonstrated for the first
time, to our knowledge, that estrogen supplementation is
highly effective in suppressing HV-induced attacks of vari-
ant angina or coronary spasm in postmenopausal women.
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